Welcome to our dedicated page for MetaVia SEC filings (Ticker: MTVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetaVia Inc. (MTVA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on cardiometabolic diseases. MetaVia files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37809 as a Delaware corporation with principal offices in Cambridge, Massachusetts. These filings offer detailed information on clinical progress, financial results, capital market actions, and interactions with The Nasdaq Capital Market.
Among MetaVia’s recent filings are several Current Reports on Form 8-K that describe material events. One 8-K discusses a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and a subsequent 180-day extension to May 26, 2026 to regain compliance, as well as the company’s intention to consider options such as a reverse stock split. Another 8-K references the company’s press release announcing a 1-for-11 reverse stock split of its common stock, which was implemented to help meet Nasdaq’s continued listing standards. A later press release, also furnished via 8-K, reports that MetaVia regained compliance with Nasdaq’s minimum bid price requirement and that the listing matter was closed.
Other 8-K filings furnish clinical and corporate updates, including positive Phase 2a data for vanoglipel (DA-1241) in presumed MASH patients and references to improvements in HbA1c, liver inflammation, fibrosis markers, and lipidomic profiles. MetaVia also uses Form 8-K to furnish its quarterly financial results and to provide access to updated corporate presentations, which summarize the status of its DA-1726 and vanoglipel programs and outline its cardiometabolic disease strategy.
Through Stock Titan, users can review these MetaVia SEC filings in one place and use AI-powered tools to summarize key points from complex disclosures. Filings such as 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, when available, can help investors and analysts understand MetaVia’s R&D spending, clinical development milestones, capital structure changes, and Nasdaq listing compliance history. Insider transaction reports on Form 4, if filed, can also be accessed to see reported purchases or sales by MetaVia’s officers, directors, or significant shareholders.
MetaVia Inc. furnished an update on its obesity and liver-disease candidate DA-1726, sharing new Phase 1 results from a 48 mg cohort presented at EASL 2026. DA-1726 is a once-weekly dual GLP1R/GCGR agonist being developed for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
In obese but otherwise healthy adults, once-weekly 48 mg DA-1726 without dose titration was generally well tolerated, with no serious adverse events, no treatment-related discontinuations and mainly mild-to-moderate, transient gastrointestinal side effects. No clinically meaningful changes in cardiovascular measures, including heart rate and QTcF, were seen despite glucagon receptor activation.
Participants on 48 mg DA-1726 achieved a mean body-weight reduction of 6.1% at Day 26 and 9.1% at Day 54, along with notable waist reductions. Exploratory FibroScan measures showed early, noninvasive signals of liver-related improvement versus placebo, supporting further evaluation of DA-1726 in obesity and MASH as ongoing Phase 1 titration studies continue.
MetaVia Inc. announced that three late-breaking abstracts on its cardiometabolic drug candidates DA-1726 and vanoglipel have been accepted for poster presentations at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans from June 5–8, 2026.
DA-1726 is a once-weekly injectable dual GLP1R/GCGR agonist being studied for obesity and MASH. It is currently in a 16-week Phase 1 Part 3 titration study, following a Phase 1 multiple ascending dose trial where a 32 mg dose showed strong effects on weight, glucose, and waist circumference.
Vanoglipel is a GPR119 agonist in development for MASH and type 2 diabetes. Preclinical models showed improvements in liver fat, inflammation, fibrosis, and glucose control, and Phase 1a, 1b and 2a trials reported that vanoglipel was well tolerated with evidence of direct hepatic action and glucose lowering.
METAVIA INC. Schedule 13G shows Alyeska Investment Group, L.P. and related filers report beneficial ownership of 508,585 shares of Common Stock as of March 31, 2026. The filing states the shares are issuable upon exercise of warrants and pre-funded warrants but are subject to a 9.99% beneficial ownership limitation.
The filing discloses the Reporting Persons hold warrants exercisable for 2,903,220 shares and pre-funded warrants exercisable for 367,740 shares (total 3,270,960), and that based on 5,090,936 shares outstanding (per a April 7, 2026 prospectus) the 9.99% cap permits exercise of only 508,585 shares. Voting and dispositive power are reported as shared for the 508,585 shares.
MetaVia Inc. reported a net loss of $3.8M for the quarter ended March 31, 2026, similar to the prior-year loss of $3.7M. Operating expenses were $4.0M, with research and development at $2.1M and general and administrative at $1.9M. Cash and cash equivalents rose to $13.7M from $10.3M, helped by $7.1M in net proceeds from a January 2026 underwritten offering and about $0.3M from at-the-market share sales. The share count increased to 5,164,370 as of May 11, 2026, reflecting new equity and warrant exercises. The company highlights “substantial doubt” about its ability to continue as a going concern over the next year and plans to rely on additional equity, debt, warrant exercises, and potential partnerships. MetaVia continues to advance its cardiometabolic pipeline, including a Phase 2a MASH trial for vanoglipel and a multi-part Phase 1 obesity trial for DA-1726, with key DA-1726 dose-escalation data expected in the fourth quarter of 2026.
MetaVia Inc. reported first quarter 2026 results and highlighted progress for its obesity candidate DA-1726. In a Phase 1 8-week, non-titrated 48 mg cohort, DA-1726 achieved 9.1% weight loss with improved glucose control, waist reduction and liver benefit, with a favorable safety profile.
The company has dosed the first patient in Part 3 of its Phase 1 trial using 48 mg and 64 mg titration regimens, with data expected in the fourth quarter of 2026. For the quarter ended March 31, 2026, MetaVia reported a net loss of $3,823,000 versus $3,671,000 a year ago, and basic and diluted loss per share of $0.79 versus $3.93, reflecting a higher share count.
Cash and cash equivalents were $13,731,000 as of March 31, 2026 compared with $10,278,000 at year-end 2025, and stockholders’ equity increased to $9,073,000 from $5,333,000. The 8-K furnishes the earnings press release and an updated corporate presentation, which include additional clinical and financial details.
MetaVia Inc. furnished an update highlighting progress for its obesity drug candidate DA-1726. A late-breaking abstract on DA-1726, a dual oxyntomodulin analog targeting GLP-1 and glucagon receptors, has been accepted for a poster presentation at the EASL Congress 2026 in Barcelona.
The company notes DA-1726 is being evaluated in a 16-week Phase 1 Part 3 titration study aimed at optimizing higher dose levels and tolerability, with data expected in the fourth quarter of the year. Prior Phase 1 multiple ascending dose results in obesity showed best-in-class potential for weight loss, glucose control, and waist reduction compared to existing GLP-1 therapies in pre-clinical and early clinical work.
MetaVia Inc. is asking stockholders to vote at a virtual 2026 annual meeting on June 8, 2026. Proposals include electing two Class I directors, ratifying the independent registered public accounting firm, approving a reverse split amendment to the certificate of incorporation, amending the 2022 equity incentive plan, and authorizing potential adjournment.
Stockholders of record on April 13, 2026, when 5,164,370 shares of common stock were outstanding, are entitled to one vote per share. The Board unanimously recommends voting “FOR ALL” director nominees and “FOR” each other proposal, and explains detailed voting mechanics for abstentions, broker non-votes and quorum in the proxy.
MetaVia Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held June 8, 2026. The Board recommends voting FOR election of two Class I directors, ratification of the independent auditor, approval of a reverse stock split amendment, approval of an amendment to the 2022 Equity Incentive Plan, and adjournment if needed. Only holders of record as of April 13, 2026 may vote; there were 5,164,370 shares outstanding on that date. The meeting will be virtual at www.virtualshareholdermeeting.com/MTVA2026; proxies may be submitted online or by mail prior to the meeting.
MetaVia Inc. has dosed the first patient in Part 3 of its Phase 1 trial of DA-1726, a dual GLP-1/glucagon agonist for obesity. This higher-dose study runs over 16 weeks and compares one-step titration to 48 mg with a two-step regimen reaching 64 mg in obese, otherwise healthy adults.
The company highlights earlier Phase 1 data showing approximately 9% weight loss at a 48 mg dose, with reductions in waist circumference, improved glycemic control, and early signs of liver benefit, alongside a favorable tolerability profile. Part 3 is designed to test whether higher therapeutic doses can be reached more quickly while maintaining tolerability, with data expected in the fourth quarter of 2026.